Evidence map›Paper›PMID 41879995›Full record

ReviewUrologie (Heidelberg, Germany)2026

[Perioperative therapy for muscle-invasive bladder cancer-current treatment concepts].

Günter Niegisch, Georgios Gakis, Carsten H Ohlmann, Ruth Knüchel-Clarke, Dirk Beyersdorff, Oliver Rick, Klaus Golka, Miriam Hegemann, Peter J Goebell, Philipp Maisch and 1 more

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Günter NiegischKlinik für Urologie, Bereich konservative urologische Onkologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. uro-onkologie@med.uni-duesseldorf.de.
Georgios GakisKlinik und Poliklinik für Urologie, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland.
Carsten H OhlmannInterdisziplinäre Arbeitsgruppe HarnblasenCarcinom (IABC) der DKG, Berlin, Deutschland.
Ruth Knüchel-ClarkeInstitut für Pathologie, Uniklinik RWTH Aachen, Aachen, Deutschland.
Dirk BeyersdorffKlinik und Poliklinik für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Oliver RickFachklinik für onkologische Rehabilitation, Klinik Reinhardshöhe, Bad Wildungen, Deutschland.
Klaus GolkaInterdisziplinäre Arbeitsgruppe HarnblasenCarcinom (IABC) der DKG, Berlin, Deutschland.
Miriam HegemannKlinik für Urologie, St. Antonius-Hospital Gronau, Gronau, Deutschland.
Peter J GoebellUrologische und Kinderurologische Klinik, Uniklinik Erlangen, Erlangen, Deutschland.
Philipp MaischInterdisziplinäre Arbeitsgruppe HarnblasenCarcinom (IABC) der DKG, Berlin, Deutschland.
Jürgen GschwendInterdisziplinäre Arbeitsgruppe HarnblasenCarcinom (IABC) der DKG, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The updated version of the German S3 guideline for bladder cancer introduces several changes in the areas of diagnostics, perioperative systemic therapy, and rehabilitation, as well as psycho-oncological and palliative care for bladder cancer patients. In urinary diagnostics, the Paris system, including a quality algorithm, has been introduced to improve the comparability of cytological findings. Imaging diagnostics now recommends multiparametric magnetic resonance imaging (MRI) with Vesical Imaging-Reporting and Data System (VI-RADS) reporting as an alternative or complement to computed tomography (CT) scans. CT urography remains the gold standard for the upper urinary tract, while intravenous pyelography (IVP) is no longer recommended. In perioperative systemic therapy, the importance of multidisciplinary case conferences for muscle-invasive bladder cancer (MIBC) is emphasized to enable as many patients as possible to receive perioperative systemic therapy. Rehabilitation now follows quality criteria (multiprofessional teams, long-term concepts) and includes an expanded assessment of physical and psychological burdens. Particularly relevant is the treatment of sexual dysfunction in women after cystectomy. In psycho-oncology and palliative medicine, early integration of the S3 guidelines is required, including advanced care planning (ACP) starting from the diagnosis of advanced tumors. These changes aim for higher diagnostic accuracy, better treatment planning, and holistic patient care.

Indexed as

Perioperative CareUrinary Bladder NeoplasmsCombined Modality TherapyCystectomyFemaleGermanyHumansMaleNeoplasm InvasivenessPalliative CareBladder cancerGuidelinePerioperative systemic therapyRehabilitationUrinalysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.